賽生藥業(06600.HK)與美納里尼於中國就VABOREM建立許可及合作協議

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

賽生藥業(06600.HK)與美納里尼於中國就VABOREM建立許可及合作協議

阿思達克 08-15 12:08

賽生藥業(06600.HK)公布，公司與美納里尼旗下A. Menarini Asia-Pacific Holdings Pte. Ltd.訂立一項許可及合作協議，授予集團根據此前美納里尼與Melinta Therapeutics的許可協議，於中國獨家開發及商業化Vaborem。該等許可協議項下擬進行的交易旨在擴大治療選擇，以應對耐藥菌感染的公共衛生威脅，特別是碳青霉烯類耐藥腸桿菌科細菌感染。

賽生藥業(06600.HK)

Relevant Stocks

賽生藥業(06600.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

賽生藥業(06600.HK)與美納里尼於中國就VABOREM建立許可及合作協議

Services

About Us

Agreement Statement